Products for Out-Licensing

Products Out-Licensing

NAL develops novel dosage forms and proprietary drug delivery systems based on Company’s captive Drug Delivery System (“DDS”) technologies. NAL expects to partner with pharmaceutical companies for the development and commercialization of the NAL products in global markets.

The partial listing of NAL’s products is outlined below. As we have not disclosed the complete list of our proprietary DDS products under development, please write to us at business@nalpharma.com to know more about NAL’s products and partnering opportunities.

 

Oncology and Supportive Oncology
 
Products Marketed or Under Development (Partial Listing)
Proposed US Filing
NAL1845 Albumin-bound Paclitaxel Injection for Cancers
505(b)(2) NDA
NAL1872 Doxorubicin Liposome Injection for Cancers
ANDA
NAL1877 Leuprolide Acetate Microsphere Injection for Prostate Cancer
ANDA
NAL1899 Pomalidomide Capsule for Multiple Myeloma
ANDA
NAL1238 Fentanyl 3-Day Patch for Severe Pain
ANDA
NAL1239 Fentanyl ODF for Breakthrough Severe Pain
505(b)(2) NDA
Top